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Background
TNF-inhibitors are valuable treatment options for adult
AS but are not approved for juvenile AS.
Aim
To determine efficacy of adalimumab (ADA) in juvenile
AS in a 12 wks double blind placebo controlled trial.
Methods
In total 32 subjects aged from 12 to 17 years suffering
from juvenile AS were enrolled into the clinical trial
HUM06-037. All subjects were randomized and
included in the ITT analysis, among them 2 who termi-
nated the treatment prematurely after 3 injections due
to insufficient efficacy (one of each group) and were
label as non-responders.
Results
17 patients were randomized to receive ADA 40mg/
2wks and 15 patients received placebo. Stable doses of
NSAIDs and low dose of corticosteroids (≤10 mg per
day) were permitted. In the ADA group a decrease of all
disease activity parameters was noted at wk 12: BASDAI
spinal inflammation score -66% (p<0.001); back pain
score -48% (p<0.005); BASFI score -47 % (p<0.02);
CHAQ-DI score -65% (p<0.005); ESR -75% (p<0.05) and
finally the CRP - 80% (p=0.07).
ASAS20 and 40 response rates after 4, 8 and 12 weeks
were higher on ADA than in the PLC group (table 1)
During the 12 wks controlled phase 26 AEs occurred
in 10 pts. on PLC compared to 25 AEs in 11 pts on
ADA. Injection site reactions were the most common
adverse event (10 on PLC, 11 on ADA). There were
16 various infections occurring in the double blind
phase, 6 on PLC, 10 on ADA. 2 SAEs occurred on
ADA.
Conclusions
This small placebo controlled trial demonstrated signifi-
cant effects of adalimumab treatment in patients with
juvenile ankylosing spondylitis.
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Table 1 per protocol analysis
ASAS20 ASAS40
Wk. PLC ADA p PLC ADA p
4 4 (31%) 9 (56%) 0.24 3 (23%) 7 (44%) 0.19
8 3 (23%) 10 (63%) 0.03* 3 (23%) 9 (56%) 0.07
12 4 (31%) 9 (63%) 0.17 4 (31) 9 (56%) 0.17
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